Asia-Pacific Acute Coronary Syndrome Market, By Type (Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, and Unstable Angina), Diagnosis (Stress Test, Blood Tests, Imaging and Others), Treatment (Medication and Surgery), End User (Hospitals and Clinics, Diagnostic Centers, Academic Institutes and Others)- Industry Trends and Forecast to 2029.
Asia-Pacific Acute Coronary Syndrome Market Analysis and Insights
Asia-Pacific acute coronary syndrome market is expected to gain significant growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.1% in the forecast period of 2022 to 2029 and is expected to reach USD 3,304.22 million by 2029. The major factors driving the growth of the acute coronary syndrome market are rise in prevalence of chronic diseases, such as coronary artery disease, ischemic heart disease, and vascular diseases, growing geriatric population, wide range of products offered by market players leading the acute coronary syndrome market to grow in future.
Acute coronary syndrome refers to a group of diseases in which blood flow to the heart decreases. Conditions related to ACS include ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina. It is a type of Coronary Heart Disease (CHD), which is responsible for one-third of total deaths in people older than 35. Some forms of CHD can be asymptomatic, but ACS is always symptomatic.
Acute coronary syndrome (ACS) is a manifestation of coronary heart disease (CHD) and usually a result of plaque disruption in coronary arteries (atherosclerosis). The common risk factors for the disease are smoking, hypertension, diabetes, hyperlipidemia, physical inactivity, family obesity, and poor nutritional practices. Cocaine abuse can also lead to vasospasm. A family history of early myocardial infarction (55 years of age) is also a high-risk factor.
Asia-Pacific acute coronary syndrome market report provides details of market share, new developments, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, products approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Type (Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, and Unstable Angina), Diagnosis (Stress Test, Blood Tests, Imaging and Others), Treatment (Medication and Surgery), End User (Hospitals and Clinics, Diagnostic Centers, Academic Institutes and Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific.
|
|
Market Players Covered
|
AstraZeneca, Daiichi Sankyo company, Johnson & Johnson Service Inc., Amgen Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc, Sanofi, CSL Behring, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter, Dr. Reddy’s Laboratories, Merck & Co., Inc. and Novartis AG and among others.
|
Acute Coronary Syndrome Market Dynamics
Drivers
- Rise in Prevalence of Chronic Diseases, such as Coronary Artery Disease, Ischemic Heart Disease, and Vascular Diseases
As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence of chronic heart and vascular diseases would help in finding novel solutions, and developing the cardiology and vascular devices would aid in more collaborations and partnerships with market players in the U.S., Europe, and Asia Pacific region. This signifies that the increase in research and development investment for the discovery and development of treatments of acute coronary syndrome boosts the market growth.
- Growing Geriatric Population
The number of elderly people reporting respective cardiovascular diseases is high. Owing to this, it is anticipated that the ever-increasing geriatric population, which is expected to rise in future years worldwide mainly in Middle East and Africa& Asia-Pacific region, creates an opportunity for market growth in the forecast period.
- Wide Range of Products Offered by Market Players
Strategic product launches and collaborations done by major companies in interventional cardiology and peripheral vascular devices have opened up an opportunity to expand their business in various regions. This strategy is allowing the companies to strengthen their footprints in the market. Therefore, it is predicted that strategic initiative is the golden opportunity for the market players to accelerate their revenue growth in the market.
Opportunities
- Surge in Technological Advancements for Cardiovascular Disease
As technology advances rapidly, it improves how one manages cardiovascular diseases. In addition, recent healthcare monitoring applications and gadgets have enhanced the connection between patients and healthcare providers to update treatment plans and improve health outcomes. Thus, this is expected to create a significant opportunity for the global acute coronary syndrome market in the forecast period.
Also, governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.
Restraints/Challenges
Rise in cost of the therapeutic surgery and lack of accessibility of disease management services and support in low economic countries are the restrains and challenges for the growth of acute coronary syndrome market.
The increased intricacy and cost of the cardiology devices and robust investments would increase the costs. The increased cost would result in delayed treatment of the patients in hospitals and clinics and clearance of these product is very rigorous and time-consuming many of the products find it difficult to get approved due to not complying with the regulations which may hamper the market growth.
This acute coronary syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on acute coronary syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In November 2021, Merck, announced the successful completion of the acquisition of Acceleron Pharma Inc. It is an important and strategic opportunity for company to continue growing their cardiovascular portfolio and pipeline that builds on long and proud legacy in cardiovascular disease and further bolsters company’s business development strategy fueled by Acceleron’s groundbreaking research.
Asia-Pacific Acute Coronary Syndrome Market Scope
Asia-Pacific acute coronary syndrome market is categorized based on type, diagnosis, treatment and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Non-St-Elevation Myocardial Infarction
- St-Elevation Myocardial Infarction
- Unstable Angina
On the basis of type, the Asia-Pacific acute coronary syndrome market is segmented into non-St-elevation myocardial infarction, St-elevation myocardial infarction and unstable angina.
Diagnosis
- Stress Test
- Blood Tests
- Imaging
- Others
On the basis of diagnosis, the Asia-Pacific acute coronary syndrome market is segmented into stress test, blood test, imagining and others.
Treatment
- Medication
- Surgery
On the basis of treatment, the Asia-Pacific acute coronary syndrome market is segmented into medication and surgery.
End User
- Hospitals and Clinics
- Diagnostic Centers
- Academic Institutes
- Others
On the basis of end user, the Asia-Pacific acute coronary syndrome market is segmented into hospitals and clinics, diagnostic centers, academic institutes and others.
Acute Coronary Syndrome Market Regional Analysis/Insights
Asia-Pacific acute coronary syndrome market is further segmented into major countries including China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific.
China in Asia-Pacific dominates the acute coronary market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the well-developed healthcare infrastructure in the country and increasing patient population.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Acute Coronary Syndrome Market Share Analysis
Asia-Pacific acute coronary syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the Asia-Pacific acute coronary syndrome market.
Some of the major prominent participants operating in the Asia-Pacific acute coronary syndrome market are Movianto (U.S.), Sharp (U.S.),Thermo Fisher Scientific Inc.,(U.S.), Catalent, Inc (U.S.), PCI Pharma Services (U.S.), Almac Group (U.K.), PAREXEL International Corporation (U.S.), Bionical Ltd. (U.K.), Alium Medical Limited (U.K.), MYODERM (U.K.), Clinigen Group plc (U.K.), Ancillare, LP (U.S.), SIRO Clinpharm (India) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (U.S.) Biocair (U.K.) and others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, GlobalVsRegional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-